Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Xavier Mignard1, Nouha Chaabane2, Vincent Fallet2

  • 1Sorbonne Université, GRC N° 04, Theranoscan, AP-HP, Hôpital Tenon, F-75020, Paris, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

End-of-life management and causes of death in ALK-positive non-small cell lung cancer in France: a multicentric analysis.

Translational lung cancer research·2026
Same author

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Cancer discovery·2026
Same author

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.

Cancer cell·2026
Same author

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Resting energy expenditure as a predictor of immune checkpoint inhibitors response in older patients with non-small cell metastatic lung cancer: A pooled analysis of two prospective cohort studies.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

The STING HAQ haplotype and clinical non-penetrance in COPA syndrome.

The Journal of experimental medicine·2026

Immune checkpoint inhibitors (ICIs) boost anti-tumoral responses by blocking PD-1 and CTLA-4. This review explores their use in non-small cell lung cancer and other thoracic malignancies, including combination therapies.

Area of Science:

  • Oncology
  • Immunology
  • Thoracic Malignancies

Background:

  • Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting molecular interactions that suppress anti-tumoral immune responses.
  • Programmed Death 1 (PD-1) and Cytotoxic T-Lymphocyte Associated-4 (CTLA-4) are key immune checkpoints.
  • ICIs are increasingly used in advanced non-small cell lung cancer (NSCLC) treatment.

Purpose of the Study:

  • To provide an overview of the current state and future perspectives of ICIs in thoracic oncology.
  • To discuss the application of ICIs in various stages of NSCLC and other thoracic cancers.
  • To explore combination strategies involving ICIs.

Main Methods:

  • Review of current literature and clinical trial data on ICIs in thoracic cancers.
Keywords:
CBNPCCombinaisonsCombinationsImmune checkpointInhibiteursNSCLCOncologie thoraciquePerspectivesThoracic oncologydu checkpointimmunitaireinhibitors

Related Experiment Videos

  • Analysis of approved and investigational ICI therapies.
  • Discussion of treatment paradigms and combination approaches.

    • Main Results:

    • Pembrolizumab and nivolumab (anti-PD-1) are approved for advanced NSCLC, with pembrolizumab also indicated for first-line treatment in specific patient populations.
    • Atezolizumab is nearing approval for second-line treatment.
    • Numerous studies are evaluating ICIs in early-stage NSCLC, other thoracic cancers, and combination therapies.

    Conclusions:

    • ICIs represent a significant advancement in thoracic oncology, particularly for NSCLC.
    • Future research focuses on expanding ICI applications to earlier disease stages, other thoracic malignancies, and novel combination regimens.
    • Combination therapies hold promise for enhancing ICI efficacy and overcoming resistance.